Workflow
Productivity program
icon
Search documents
JDE Peet’s reports strategic and operational progress - Confirms 2025 outlook
Globenewswire· 2025-10-27 07:00
Core Insights - JDE Peet's provided an interim update on its strategic and operational progress for Q3 2025, highlighting the implementation of its 'Reignite the Amazing' strategy and productivity program [1][2] Strategic and Operational Initiatives - The 'Reignite the Amazing' strategy was launched on July 1, 2025, and is currently being executed [2] - The company has completed the full integration of the U.S. capsules business into Peet's and is transitioning its commercial route-to-market strategy in the U.S. [7] - JDE Peet's exited its low-margin Food Ingredients business in Asia and announced two additional plant closures in Brazil and the U.S. as part of its manufacturing optimization [7] - Brand rationalization is in progress, with 15 long-tail brands set to transition over the next six months [7] - The company is fostering a culture of agility, ownership, and transparency, driven by four newly defined values [7] Business Performance - Overall Q3 performance is in line with company expectations, influenced by retailer negotiations and customer pre-buying in H1 [7] - The company remains on track to achieve its 2025 outlook as outlined in the H1 2025 results announcement [7] - Green coffee prices are significantly elevated and increasingly volatile, impacting the company's cost structure [7] - Approximately 96% of the second wave of global price negotiations, initiated in July, has been completed [7] Financial and Regulatory Updates - The share buyback program was terminated on September 1, 2025 [7] - A regulatory anti-trust filing has been submitted in the U.S. [7] - Positive advice was received from JDE Peet's Dutch Works Council regarding the ongoing transaction with Keurig Dr Pepper [7] - The closing of the transaction is expected in H1 2026, pending customary pre-offer and closing conditions [7]
Genomma Lab Internacional Announces Results for the Third Quarter 2025
Prnewswire· 2025-10-23 01:13
Core Insights - Genomma Lab reported a challenging third quarter in 2025, with like-for-like sales decreasing by 2.9% due to a weak summer season affecting beverage sales in central Mexico and a softer overall consumption environment [2][3] - Despite the topline pressure, the company maintained a healthy EBITDA margin of 23.7%, reflecting strong business fundamentals and cost containment efforts [2][4] - The productivity program initiated in 2023 is expected to generate cumulative savings of MXN 3.0 billion by 2026, with MXN 1.1 billion already secured this year [2] Financial Performance - Like-for-like sales decreased by 2.9%, primarily due to a tough consumption environment in Mexico and a weak summer season impacting the beverage category, partially offset by growth in Brazil, Chile, Central America, and the Andean cluster [3] - Net sales for Q3 2025 were MXN 4,441.4 million, a decrease of 12.8% compared to Q3 2024 [3] - Gross profit was MXN 2,836.2 million, representing 63.9% of net sales, down from 64.3% in the previous year [3] - EBITDA reached MXN 1,053.6 million, maintaining a margin of 23.7%, with a slight increase of 2 basis points driven by manufacturing cost efficiencies [4] - Net income decreased by 34.2% primarily due to non-cash accumulated hyperinflationary accounting effects related to a 53% depreciation of the Argentine peso [5] Proforma Metrics - Proforma net income decreased by 3.0%, reflecting a strong EBITDA margin and lower net interest expenses [5] - Proforma EPS stood at MXN 0.63 per share, a decrease of 3.0% compared to the previous year [5]